370-98-9

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-METHYLAMINO-ETHYL)-PHENOL is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to form essential molecular structures and functional groups in drug molecules.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 4-(2-METHYLAMINO-ETHYL)-PHENOL serves as a building block for the creation of diverse organic compounds, leveraging its reactive functional groups for further chemical reactions and modifications.
Used in Research and Development:
4-(2-METHYLAMINO-ETHYL)-PHENOL is utilized in research settings for the exploration of new chemical reactions, the development of novel synthetic pathways, and the study of its properties and potential applications in various chemical and biological processes.

InChI:InChI=1/C9H13NO.ClH/c1-10-7-6-8-2-4-9(11)5-3-8;/h2-5,10-11H,6-7H2,1H3;1H

Upstream product

• 4091-50-3 N-methylhomoanisylamine 
• 537-49-5 N-methyl-L-tyrosine 
• 19897-63-3 N-methyltyrosine 
• 175287-92-0 N-(4-methoxy-phenethyl)-benzenesulfonamide 
• 74-88-4 methyl iodide 
• 57933-99-0 Carbonic acid 4-[2-(methyl-vinyloxycarbonyl-amino)-ethyl]-phenyl ester vinyl ester 
• 55-81-2 4-Methoxyphenethylamine 
• 539-15-1 N,N-dimethyltyramine 
• 61186-07-0 N-methyl-N-(2-[4-hydroxyphenyl]ethyl)amine hydrobromide 
• 14425-64-0 4-methoxyphenethyl bromide 
• 74-89-5 methylamine 
• 67-56-1 methanol 
• 51-67-2 tyrosamine 
• 14140-15-9 4-(2-bromoethyl)phenol 

Downstream Products

• 859324-01-9 4-(2-methylamino-ethyl)-2-nitro-phenol 
• 1976-98-3 (4-hydroxyphenethyl)trimethylammonium iodide 
• 24958-44-9 2-bromo-4-methoxy-5-hydroxy-N-[2-(4-hydroxyphenyl)-ethyl]-N-methylbenzamide 
• 112196-70-0 N-tert-butoxycarbonyl-N-methyl-2-(4-hydroxyphenyl)-ethylamine 
• 13062-76-5 N-Methyltyramine hydrochloride 
• 857945-41-6 N-(4-hydroxy-3-nitro-phenethyl)-N-methyl-acetamide 

Relevant academic research and scientific papers

Selective Monomethylation of Amines with Methanol as the C1 Source

The N-monomethyl functionality is a common motif in a variety of synthetic and natural compounds. However, facile access to such compounds remains a fundamental challenge in organic synthesis owing to selectivity issues caused by overmethylation. To address this issue, we have developed a method for the selective, catalytic monomethylation of various structurally and functionally diverse amines, including typically problematic primary aliphatic amines, using methanol as the methylating agent, which is a sustainable chemical feedstock. Kinetic control of the aliphatic amine monomethylation was achieved by using a readily available ruthenium catalyst at an adequate temperature under hydrogen pressure. Various substrates including bio-related molecules and pharmaceuticals were selectively monomethylated, demonstrating the general utility of the developed method.

SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE

The invention provides compounds of formula I and compositions thereof. The invention further provides methods of using the compounds and compositions. The compounds of the invention can provide high affinity binding to sigma-1 receptors in a mammal. The compounds can exhibit selectivity for the sigma-1 receptor over the sigma-2 receptor. The compounds and compositions of the invention can also be used to treat conditions that involve the sigma-1 receptor, such as addiction, cardiovascular conditions, and cancer, for example, cancer of the breast, lung, prostate, ovarian, colorectal, or the CNS.

Process for making galantamine

A novel process for the preparation of N-methyl-N-(2-[4-hydroxyphenyl]ethyl)-5-hydroxy-4-methoxy benzene carboxamide, which is useful as an intermediate in the synthesis of (?)-galantamine, comprises the reaction of a 5-hydroxy-4-methoxy benzoic acid derivative with N-methyl-N-(2-[4-hydroxyphenyl]ethyl)amine.

Compounds and pharmaceutical use thereof

PCT No. PCT/JP97/00291 Sec. 371 Date Aug. 6, 1998 Sec. 102(e) Date Aug. 6, 1998 PCT Filed Feb. 6, 1997 PCT Pub. No. WO97/29079 PCT Pub. Date Aug. 14, 1997The compounds of the formula (I) wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The Compound (I) and pharmaceutically acceptable salts thereof of the present invention selectively act on cannabinoid receptors, particularly peripheral receptors, cause less side effects on the central system, and have superior immunoregulating action, antiinflammatory action, antiallergic action and therapeutic effect on nephritis. Therefore, they are useful as cannabinoid receptor, particularly peripheral cannabinoid receptor activators and antagonists, immunoregulators, therapeutic agents for autoimmune diseases, antiinflammatory agents, antiallergic agents and therapeutic agents for nephritis.